Case Study

Integrated Strategies for Achieving Regulatory Milestones Faster: An Extended Release Case Study With Ensysce Biosciences

Source: Quotient Sciences
Medical scientists analyzing research-GettyImages-1413600685

A sponsor was developing a novel opioid combination product for the potential treatment of moderate to severe pain designed to prevent both abuse and overdose. Pre-clinical data of immediate-release (IR) nafamostat demonstrated protection from overdose in animal models, but initial clinical data showed that IR nafamostat may not be sufficient in humans. To determine if an extended-release (ER) formulation might be required, three different variables would need to be evaluated clinically: ER release rate, ER/IR ratio, and the nafamostat dose level.

Quotient Sciences’ Translational Pharmaceutics platform integrates formulation development, real-time adaptive GMP manufacturing, and clinical testing to accelerate drug development and can be applied to enable drug product optimization in real-time based on arising clinical data using rapid ‘make-test’ cycles. Learn how the Translational Pharmaceutics platform reduced development timelines and allowed the sponsor to find the optimal nafamostat formulation without adding unnecessary delays.

access the Case Study!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Outsourced Pharma